10-Q: Anteris Tech Q2 Loss Widens Amid Paradigm Trial Preparations

Anteris Technologies Global Corp. reports increased losses in Q2 2025 as it ramps up manufacturing and clinical infrastructure for the PARADIGM Trial.

Summary

• Anteris Technologies Global Corp. reports a net loss of $21.06 million for the three months ended June 30, 2025, compared to a net loss of $18.82 million for the same period in 2024.
• The company's net sales for the quarter were $0.62 million, slightly down from $0.63 million in the prior year.
• Research and development expenses increased to $16.34 million, up from $12.63 million in the same quarter last year, driven by manufacturing upscaling and PARADIGM Trial preparations.
• Selling, general, and administrative expenses decreased to $5.01 million from $6.16 million year-over-year.
• For the six months ended June 30, 2025, the net loss was $42.99 million, compared to $34.97 million in 2024.
• The company had $28.44 million in cash, cash equivalents, and restricted cash as of June 30, 2025, down from $70.46 million at the end of 2024.
• The company expects to begin enrollment in the PARADIGM Trial in the third quarter of 2025.

Sentiment

Score: 4

Explanation: The filing contains both positive and negative elements. The progress in clinical trial preparation and manufacturing capacity expansion are positive, but the increased losses, decreased cash balance, and material weaknesses in internal control are negative.

Positives

• 79 sites are now qualified to participate in the PARADIGM Trial.
• Manufacturing capacity has been increased to at least three times the 2024 capacity levels.
• The company has submitted an IDE for the PARADIGM Trial to the FDA.
• The company has a track record of successfully raising new capital and entering into debt facilities.

Negatives

• The company incurred a net loss of $21.06 million for the three months ended June 30, 2025, and $42.99 million for the six months ended June 30, 2025.
• The company's cash balance decreased from $70.46 million at the end of 2024 to $28.44 million as of June 30, 2025.
• The company's auditors have identified material weaknesses in the design and operating effectiveness of its internal control over financial reporting.
• The company's ability to continue as a going concern is dependent upon securing additional funds.

Risks

• The company's ability to access capital may be impacted by various factors including economic conditions, a decline in investor confidence and sub-optimal preclinical or clinical outcomes from trials and studies.
• Limited access to capital may delay the development of our product portfolio, extend the timeline to commercialization, or lead to other operational impacts.
• The company may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all.
• The company's future capital requirements are difficult to forecast and will depend on many factors, including the scope, results and timing of clinical trials, the costs of preparing and completing the PARADIGM Trial of our DurAVR THV system, the costs and time required to obtain pre-market approval from the FDA for our DurAVR THV system and the costs of establishing marketing, sales and distribution capabilities.

Future Outlook

The company anticipates enrollment in the PARADIGM Trial to begin in the third quarter of 2025 and expects to continue incurring losses in the near future until regulatory approvals are obtained and sales commence.

Management Comments

• The Anteris team made considerable progress strengthening its clinical infrastructure and manufacturing capabilities in preparation for the PARADIGM Trial.
• A key focus was the qualification of trial sites, including feasibility assessments to confirm each sites access to a suitable aortic stenosis patient population and their capacity to conduct the PARADIGM Trial to the highest standards.
• Ongoing collaborative work with the FDA to progress the IDE application has been a major focus this quarter, in addition to proactively scaling the manufacturing of all key products to meet the anticipated inventory demands of the upcoming PARADIGM Trial.

Industry Context

The company is positioning its DurAVR THV system as a unique product opportunity in the treatment of aortic stenosis, a market dominated by TAVR systems from competitors like SAPIEN and Evolut. The PARADIGM Trial aims to demonstrate non-inferiority to these established systems.

Comparison to Industry Standards

• The filing mentions the DurAVR THV system will be compared to commercially available TAVR systems (SAPIEN or Evolut series THV) for treatment of subjects with severe calcific aortic stenosis.
• The ADAPT tissue has been clinically demonstrated to be calcium free for up to 10 years post-procedure, according to Performance of the ADAPT-Treated CardioCel Scaffold in Pediatric Patients With Congenital Cardiac Anomalies: Medium to Long-Term Outcomes , published by William Neethling et. al., and has been distributed for use in over 55,000 patients globally in other indications.

Corporate Governance

Legal Proceedings

• The Company is involved in various ongoing proceedings arising in the normal course of business, including proceedings related to product, labor, intellectual property and other matters. The Company is not party to any material legal proceedings, and no such proceedings are, to managements knowledge, threatened against us.

Stakeholder Impact

• Shareholders: Dilution may occur if the company raises additional capital through equity offerings.
• Employees: The company is expanding headcount, particularly in manufacturing and clinical roles.
• Customers: The company is preparing for the commercialization of the DurAVR THV system, which could provide a new treatment option for aortic stenosis.
• Creditors: The company may seek to raise additional capital through debt financings, which could impact its creditworthiness.

Next Steps

• Commence enrollment in the PARADIGM Trial in the third quarter of 2025.
• Continue collaborative work with the FDA to progress the IDE application.
• Continue scaling the manufacturing of all key products to meet the anticipated inventory demands of the upcoming PARADIGM Trial.
• Complete documentation of entity-level and key financial reporting processes and controls.
• Undertake a review of segregation of duties across financial reporting streams.

Key Dates

Recommendation

Given the increased losses, decreased cash balance, and material weaknesses in internal control, a hold recommendation is appropriate. The company's future prospects depend on the successful completion of the PARADIGM Trial and obtaining regulatory approvals, which are subject to significant risks and uncertainties. While the company is making progress in these areas, the current financial situation warrants caution.

Keywords

DurAVR THV, aortic stenosis, PARADIGM Trial, ADAPT tissue, TAVR, Anteris Technologies, SEC filing, clinical trial, FDA approval, financial results